These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38216214)

  • 41. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
    Smith KW; White CM
    J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the Inclisiran Safety in High-Risk Populations.
    Jiang X; Zhang Z; Ding H
    J Am Coll Cardiol; 2024 Apr; 83(13):e127. PubMed ID: 38538206
    [No Abstract]   [Full Text] [Related]  

  • 44. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book.
    Santos RD; Rocha VZ
    Eur Heart J; 2023 Jan; 44(2):139-141. PubMed ID: 36331316
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
    Wright RS; Koenig W; Landmesser U; Leiter LA; Raal FJ; Schwartz GG; Lesogor A; Maheux P; Stratz C; Zang X; Ray KK
    J Am Coll Cardiol; 2023 Dec; 82(24):2251-2261. PubMed ID: 38057066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reply: Evaluation of the Inclisiran Safety in High-Risk Populations.
    Wright RS; Leiter LA; Lesogor A; Ray KK
    J Am Coll Cardiol; 2024 Apr; 83(13):e129. PubMed ID: 38538207
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapeutic options to reduce LDL-cholesterol beyond statins].
    Weingärtner O; Marx N; Klose G; Laufs U
    Dtsch Med Wochenschr; 2022 Aug; 147(15):1001-1012. PubMed ID: 35915886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inclisiran (Leqvio) for LDL-cholesterol lowering.
    Med Lett Drugs Ther; 2022 Mar; 64(1646):43-45. PubMed ID: 35294427
    [No Abstract]   [Full Text] [Related]  

  • 52. Inclisiran: First Approval.
    Lamb YN
    Drugs; 2021 Feb; 81(3):389-395. PubMed ID: 33620677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
    Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.
    Giordano S; Polimeni A; Esposito G; Indolfi C; Spaccarotella C
    Curr Opin Lipidol; 2023 Aug; 34(4):133-140. PubMed ID: 36924354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclisiran: A Game Changer in a Changing Game?
    Nambi V; Agha A
    J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736
    [No Abstract]   [Full Text] [Related]  

  • 56. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia.
    Gosselin NH; Schuck VJA; Barriere O; Kulmatycki K; Margolskee A; Smith P; He Y
    Clin Pharmacol Ther; 2023 Feb; 113(2):328-338. PubMed ID: 36281788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimation of the major cardiovascular events prevention with Inclisiran.
    Cordero A; Santos-Gallego CG; Fácila L; Rodríguez-Mañero M; Bertomeu-González V; Castellano JM; Seijas-Amigo J; Núñez J; Zuazola P; González-Juanatey JR; Badimon JJ
    Atherosclerosis; 2020 Nov; 313():76-80. PubMed ID: 33032236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 60. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.
    Arnold N; Koenig W
    Curr Cardiol Rep; 2022 Nov; 24(11):1657-1667. PubMed ID: 36087240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.